Cancer nanomedicine: Smart arsenal in the war against cancer

Inorganic Chemistry Communications, Journal Year: 2025, Volume and Issue: unknown, P. 114030 - 114030

Published: Feb. 1, 2025

Language: Английский

---

Circulating RNA Markers Associated with Adenoma–Carcinoma Sequence in Colorectal Cancer

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(4), P. 1518 - 1518

Published: Feb. 11, 2025

Colorectal cancer progresses through a well-defined adenoma–carcinoma sequence (ACS), which is pivotal for early detection and intervention. While ACS-based surveillance has been instrumental, its reliance on tissue sampling limits accurate staging. Liquid biopsies, including circulating tumor DNA (ctDNA) extracellular RNA, have emerged as non-invasive alternatives, yet they primarily detect genetic alterations or passive RNA release rather than active biological processes. Thus, there need biomarkers that reflect real-time immune responses tumor–microenvironment interactions during ACS progression. This study aimed to identify associated with by analyzing blood samples from 160 individuals across five groups: colorectal cancer, advanced adenoma, non-advanced symptomatic non-disease control, healthy control. sequencing coupled gene ontology protein–protein interaction analyses identified stage-specific transcripts. Notably, IFI27 was linked the control group, DEFA4 adenoma MPO CD177 group. These findings suggest colorectal-cancer-related markers host progression, supporting their potential role in diagnoses. By addressing critical gaps detection, this advances utility of liquid biopsies screening clinical management.

Language: Английский

---

Methods for Extracellular Vesicle Isolation: Relevance for Encapsulated miRNAs in Disease Diagnosis and Treatment

Genes, Journal Year: 2025, Volume and Issue: 16(3), P. 330 - 330

Published: March 12, 2025

Extracellular vesicles (EVs) are nanovesicles that facilitate intercellular communication by carrying essential biomolecules under physiological and pathological conditions including microRNAs (miRNAs). They found in various body fluids, such as blood, urine, saliva, their levels fluctuate with disease progression, making them valuable diagnostic tools. However, isolating EVs is challenging due to small size biological complexity. Here, we summarize the principles behind most common EV isolation methods ultracentrifugation, precipitation, immunoaffinity, sorting, ultrafiltration, exclusion chromatography, microfluidics while highlighting protocol strengths weaknesses. We also review main strategies identify quantify circulating miRNAs a particular focus on EV-encapsulated miRNAs. Since these hold special clinical interest derived from superior stability therapeutic potential, information provided here should provide guidance for future research initiatives promising field of treatment based

Language: Английский

---

Liquid biopsies in cancer

Molecular Biomedicine, Journal Year: 2025, Volume and Issue: 6(1)

Published: March 20, 2025

Abstract Cancer ranks among the most lethal diseases worldwide. Tissue biopsy is currently primary method for diagnosis and biological analysis of various solid tumors. However, this has some disadvantages related to insufficient tissue specimen collection intratumoral heterogeneity. Liquid a noninvasive approach identifying cancer-related biomarkers in peripheral blood, which allows repetitive sampling across multiple time points. In field liquid biopsy, representative include circulating tumor cells (CTCs), DNA (ctDNA), exosomes. Many studies have evaluated prognostic predictive roles CTCs ctDNA Although these limitations, results appear consistently demonstrate correlations high CTC counts mutations with lower survival rates cancer patients. Similarly, reduction throughout therapy may be potential indicator treatment response advanced Moreover, biochemical characteristics can provide information about biology as well resistance mechanisms against targeted therapy. This review discusses current clinical applications patients, emphasizing its possible utility outcome prediction decision-making.

Language: Английский

---

Blood-based biomarkers in pancreatic ductal adenocarcinoma: developments over the last decade and what holds for the future- a review

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: April 22, 2025

Pancreatic Ductal Adenocarcinoma (PDAC) accounts for a significant burden of global cancer deaths worldwide. The dismal outcomes associated with PDAC can be overcome by detecting the disease early and developing tools that predict response to treatment, allowing selection most optimal treatment. Over last couple years, progress has been made in development novel biomarkers aid diagnosis, prognosis, treatment selection, monitoring response. Blood-based offer an alternative tissue-based diagnosis immense potential managing PDAC. In this review, we have discussed advances blood-based PDAC, such as DNA (mutations methylations), RNA, protein circulating tumor cells (CTC) over decade also elucidated all aspects practical implementation these clinical practice. We implementing multiomics utilizing more than one biomarker targeted therapies developed using biomarkers.

Language: Английский

---